No profile data available.
Grail, Inc. (GRAL) is a healthcare company in the DNA testing equipment industry, based in Menlo Park, United States, with about 910 full-time employees.
It reported revenue of $125.60 million for fiscal year 2024, up 34.9% from fiscal year 2023, and net income of -$2.03 billion. In Q3 2025 (the quarter ended September 30, 2025) revenue was $36.19 million, up 26.3% from a year before. United States was its largest region in fiscal year 2025, with 93% of revenue. Its market capitalization was $6.28 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2024; market data as of October 9, 2026.
, a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer.
Grail reported $125.60 million in revenue for fiscal year 2024, up 34.9% from $93.11 million in fiscal year 2023. In Q3 2025 revenue was $36.19 million.
United States: 93% of revenue by region in fiscal year 2025, followed by International (7%).
$6.28 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (DNA testing equipment) include Tempus AI, Inc. (TEM), Qiagen N.v. (QGEN), Caris Life Sciences, Inc. (CAI), Adaptive Biotechnologies Corporation (ADPT).